CMS has proposed key 2027 updates to Medicare Advantage and Part D Star Ratings aiming to streamline quality measures and modernize enrollment options to enhance care and plan accountability.
HHS-OIG audit uncovers $39.6 million in potentially improper podiatry E/M payments, urging CMS to enhance Medicare oversight in billing practices.
CMS will conduct a drug acquisition cost survey in early 2026 to collect data from hospitals under the Medicare OPPS, informing 2027 outpatient payment policies.
CMS introduces the ACCESS Model to enhance chronic care for Medicare beneficiaries using digital health tools and outcome-based payment models starting in 2026.
GAO report reveals fraud vulnerabilities in ACA marketplaces with fake enrollments approved in 2024-25, urging stronger fraud controls and verification in federal marketplaces.
CMS reveals new 2027 price caps for 15 Medicare Part D drugs, projected to save billions federally and reduce patient costs under the Inflation Reduction Act negotiations.
CMS introduces the ACCESS Model, a voluntary Medicare initiative that promotes technology-enabled chronic care solutions to improve patient outcomes and modernize Medicare treatment frameworks.
CMS unveils significant Medicare Advantage and Part D changes for 2027, including Star Ratings overhaul and increased quality bonus payments, impacting Medicare spending by $14B.
CMS announces 2026 updates for OPPS and ASC payment systems, including expanded site neutral payments, skin substitute product unbundling, IPO list phase-out, and new hospital price transparency requirements.
CMS's 2027 proposed rule outlines key Medicare Advantage and Part D program updates, codifying Inflation Reduction Act changes, adjusting Star Ratings, and modernizing marketing and risk adjustment frameworks.
